Overall, we evaluated the potential of the ICG-HSA complex as a valuable fluorescence agent to improve FGS outcomes for glioblastoma patients by providing accurate resection of tumor margins via SPARC targeting of the tumor. The gene discussed is SPARC; the disease is neoplasm.